Clinical evaluation of clobetasone butyrate eye drops in the treatment of anterior uveitis and its effects on intraocular pressure.
Clobetasone butyrate has been formulated as a new steroid preparation of use in ophthalmology and has been compared with prednisolone phosphate and betamethasone phosphate in the treatment of anterior uveitis. The results from 4 double-blind, between-patient studies have shown that all 3 treatments are effective in reducing the signs and symptoms of this intraocular disease. 87% of those patients receiving clobetasone butyrate had a good or satisfactory response, but no differences in therapeutic efficacy were observed between these 3 steroid treatments. Clobetasone butyrate had little effect on intraocular pressure when compared with dexamethasone or hydrocortisone, both of which cause a significant rise in intraocular pressure.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D003907:Dexamethasone / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011897:Random Allocation; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology
D009883:Ophthalmic Solutions; C009022:prednisolone phosphate; C028994:betamethasone sodium phosphate; D003907:Dexamethasone; C010893:clobetasone butyrate; D001623:Betamethasone; D011239:Prednisolone; D002990:Clobetasol; D006854:Hydrocortisone